HGH (Somatropin)110iu
HGH (Somatropin) Canada — 110 IU Vials
Recombinant Growth Hormone
HGH (Somatropin) is a recombinant form of human growth hormone studied in laboratory settings for its role in growth factor signaling and cellular development pathways. Research often focuses on its interaction with IGF-1–related mechanisms, protein synthesis processes, and overall regulation of metabolic and structural tissue systems in controlled models.
Discount and referral codes apply at checkout. Sales, Mix & Match and payment-method discounts don't.
Kit of 10 vials — $28.00 per vial
Sold as a kit — each one you add to the cart is a complete 10-vial kit. Single vials are not sold separately.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
HGH, also known as recombinant human growth hormone (somatropin), is a synthetic peptide hormone identical in sequence to endogenous human growth hormone. It is produced using recombinant DNA technology for controlled laboratory research.
In scientific literature, HGH is studied in experimental models examining growth hormone receptor interaction, endocrine signaling cascades, and downstream cellular response systems under in vitro and preclinical research conditions.
Third-party tested for purity, identity, quantity, and dimer content.
Recombinant human growth hormone is a 191–amino acid peptide evaluated in research focused on growth hormone receptor activation and endocrine pathway signaling. Experimental studies examine receptor-binding dynamics, IGF-associated pathways, and systemic regulatory frameworks within controlled laboratory environments.
Preclinical and clinical research publications have explored its receptor interaction profile and downstream signaling behavior under structured study conditions.
Human growth hormone was originally isolated from pituitary tissue before recombinant DNA technology enabled synthetic production of somatropin. Recombinant HGH became central to endocrine research, allowing for controlled investigation of growth hormone receptor systems and downstream regulatory pathways.
Subsequent research expanded into receptor signaling, metabolic regulation models, and systemic endocrine interaction frameworks.
Laboratory investigations into recombinant human growth hormone have focused on growth hormone receptor activation models and downstream endocrine signaling pathways. Research frameworks evaluate IGF-related signaling cascades, systemic regulatory interaction, and receptor-mediated response systems under controlled in vitro and preclinical conditions.
1 of the 4 areas below are addressed directly by a paper cited on this page.
Addressed on this page by Stevenson 1988, Yudaev 1983, Lostroh 1976. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
No paper cited on this page reports on associated. This heading marks where HGH (Somatropin) is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
No paper cited on this page reports on endocrine. This heading marks where HGH (Somatropin) is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
No paper cited on this page reports on receptor, mediated or cellular. This heading marks where HGH (Somatropin) is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
The references section of this page cites 3 primary papers published between 1976 and 1988 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
HGH (Somatropin) is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for HGH (Somatropin), set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
HGH (Somatropin) is also referred to as somatropin, growth hormone, GH.
HGH (Somatropin) is commonly described online in connection with muscle growth, fat loss and improved recovery. In the research literature the same compound is filed under growth hormone receptor activation models, IGF-associated signaling pathway research and endocrine regulatory framework studies.
The 3 papers cited on this page, published between 1976 and 1988 (1 in animal models) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for HGH (Somatropin) is per lot, not per product. The current 110iu lot HGH-CA-26G-100 returned 97.945% purity, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
The lot code printed on the vial matches the code on the certificate for HGH (Somatropin). Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy HGH (Somatropin) in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
HGH (Somatropin) is supplied as lyophilized powder. It is not a peptide, and solvent behaviour follows from its own chemistry rather than from the aqueous-vehicle conventions that apply to peptide material — the published literature for this compound is the reference for solvent selection, not a general peptide protocol.
Dry storage below freezing and protection from light are the general controls. As with any lyophilized material, the powder frequently sits as a thin film at the base of the vial and is easy to mistake for an empty vial before inspection.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains 110 IU of recombinant human growth hormone in a 3mL presentation. Independent third-party testing verifies purity, identity, batch specifications, and dimer levels.
The vial contains only the peptide preparation. Any laboratory materials required for experimental procedures must be sourced separately.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
The synthetic human growth hormone fragment (32–38) increases glucose uptake in the conscious dog.
PubMedThe effect of synthetic fragment 31–44 of human growth hormone on glucose uptake by isolated adipose tissue.
PubMedDiabetogenic peptide from human growth hormone: partial purification from peptic digest and long-term action in ob/ob mice. Proc Natl Acad Sci U S A 73(7):2920–2922.
PubMedRelated
Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$59.95CAD
Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$34.95CAD
Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$54.95CAD
Out of stockPeptides
Long-Acting Amylin Analogue · 5 & 10 mg Cagrilintide is a synthetic peptide developed for controlled laboratory research involving amylin receptor signaling systems. It is structurally designed to interact with amylin-associated pathways within experimental environments.
CAG-CA-26A-0199.446%
5.62 mg / 5 mg
$69.95CAD
